Patrick Daly

Patrick Daly is an Assistant Editor at AMC Media Group.

Articles by Patrick Daly

Patrick DalyPolycythemia Vera | December 8, 2023
Rusfertide quickly induced hematocrit control and maintained improved levels over time in patients with polycythemia vera.
Read More
Patrick DalyMyeloma | December 7, 2023
Jens Hillengass, MD, PhD, covers updates from CARTITUDE that show cilta-cel is effective in early lines of therapy in MM.
Patrick DalyMyeloma | December 6, 2023
Researchers point to the poor outcomes observed with existing treatments. Here's what they found.
Patrick DalyAggressive B-Cell Lymphoma | December 5, 2023
After a median of four years of follow-up, participants in the pivotal ZUMA-2 study had a median OS of nof nearly five years.
Patrick DalyMyelodysplastic Syndromes | December 5, 2023
Venetoclax plus azacitidine was well tolerated and achieved favorable response rates in higher-risk myelodysplastic syndrome.
Patrick DalyMyelofibrosis | December 5, 2023
The study aimed to address “a substantial unmet need for therapies that alter disease trajectory" in patients with MF.
Patrick DalyMyeloproliferative Neoplasms | December 6, 2023
This is just one finding from a longitudinal analysis of phase III data from the SIMPLIFY-1 and MOMENTUM trials.
Patrick DalyAcute Myeloid Leukemia | December 1, 2023
Researchers identified which co-occurring mutations had the strongest significance and what the high incidence could mean.
Patrick DalyMyeloma | November 29, 2023
Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.
Patrick DalyMyeloma | November 29, 2023
Carfilzomib improved PFS versus bortezomib in induction therapy regimens with lenalidomide and dexamethasone in MM.
Patrick DalyMyeloma | November 29, 2023
Lenalidomide-associated ALL was seen in patients with MM, but discontinuation alone led to regression of clonal populations.
Patrick DalyChronic Lymphocytic Leukemia | November 28, 2023
Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.
Patrick DalyChronic Lymphocytic Leukemia | November 28, 2023
Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.
Patrick DalyChronic Lymphocytic Leukemia | November 28, 2023
A time-limited regimen including a PI3K inhibitor was safe and highly effective in patients with relapsed or refractory CLL.
Patrick DalyMyeloma | November 28, 2023
Patients with relapsed or refractory multiple myeloma sustained durable remissions after switching to biweekly teclistamab.
Patrick DalyMantle Cell Lymphoma | November 21, 2023
Mosunetuzumab plus polatuzumab vedotin achieved high CR rates in relapsed or refractory MCL with prior BTKi treatment.
Patrick DalyMantle Cell Lymphoma | November 21, 2023
Interspersing cytarabine in R-CHOP induction therapy did not yield significant improvements in elderly patients with MCL.
Patrick DalyMantle Cell Lymphoma | November 21, 2023
BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.
Patrick DalyMyeloma | November 16, 2023
Elranatamab was effective and well-tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.
Patrick DalyMyelofibrosis | November 16, 2023
There were no significant differences in response rates with pegylated interferon-alpha versus hydroxyurea in MPN treatment.